PUNE, India, Sept. 25, 2026 /PRNewswire/ -- The Global Clinical Trials Market was valued at USD 58.19 Billion in 2025 and is projected to grow at a 6.13% CAGR from 2026 to 2034, reaching USD 99.4 Billion by 2034, according to Maximize Market Research.

Global Clinical Trials Market

The Global Clinical Trials Market Report 2026 provides a detailed analysis of market trends, clinical research demand, trial volume, regulatory developments, biopharmaceutical R&D, technological advancements, competitive developments, therapeutic applications, and market forecasts through 2034. The market covers Phase I, Phase II, Phase III, and Phase IV, along with Interventional Trials, Observational Trials, and Expanded Access Trials, with services spanning Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services, Clinical Trial Data Management Services, and Medical Device Testing Services.

The growing number of clinical trials worldwide, increasing prevalence of chronic diseases, rising demand for personalized medicine, and expanding biopharmaceutical R&D are supporting the growth of the global clinical trials market. Increasing research activity in oncology, cardiovascular diseases, CNS conditions, diabetes, obesity, autoimmune and inflammatory diseases, and pain management is strengthening demand for clinical trial services. Growing adoption of decentralized clinical trials, virtual trials, real-world evidence, telemedicine, remote patient monitoring, AI, machine learning, and data analytics is further improving patient recruitment, clinical data collection, trial monitoring, and overall research efficiency.

Advancements in AI-driven clinical trial design, predictive analytics, adaptive trials, synthetic control arms, biomarker-driven research, wearable technologies, and remote monitoring platforms are further transforming the clinical trials landscape. Increasing collaboration among pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions, healthcare systems, and patient advocacy groups is creating new opportunities for market participants. Investments in oncology research, rare diseases, gene therapies, personalized therapies, and decentralized trial infrastructure are expected to strengthen the global clinical trials market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/189646/

Global Clinical Trials Market gains momentum as rising biopharmaceutical R&D, increasing demand for personalized medicine, growing clinical trial activity, expansion of decentralized and virtual trials, adoption of AI and machine learning, and greater use of real-world evidence accelerate clinical research innovation: Maximize Market Research unveils key insights.

Global Clinical Trials Market Size & Forecast

Global Clinical Trials Market Trends & Insights

- North America leads the Global Clinical Trials Market, supported by high clinical research activity, strong pharmaceutical and biotechnology infrastructure, significant cancer burden, government support, and the presence of major clinical research organizations and pharmaceutical companies. The United States remains a key contributor to regional trial activity.

- Europe and North America account for a substantial share of global clinical trials, while expanding research activity across emerging markets is creating additional opportunities for clinical trial sponsors, CROs, research institutions, and service providers.

- Rising demand for personalized medicine, increasing prevalence of chronic diseases, growing oncology research, and higher biopharmaceutical R&D expenditure are accelerating clinical trial activity across drug development, vaccines, biologics, advanced therapies, and therapeutic research.

- Decentralized clinical trials, virtual trials, telemedicine, remote patient monitoring, AI, machine learning, data analytics, and real-world evidence are gaining importance as sponsors seek faster patient recruitment, improved data collection, better monitoring, and more efficient trial execution.

- AI-driven protocol design, predictive analytics, adaptive trial models, synthetic control arms, biomarker-driven research, wearable technologies, and remote monitoring platforms are reshaping the clinical trials landscape. Strategic collaborations, healthcare-system partnerships, patient-centric trial models, and technology integration are creating new opportunities for Clinical Trials Market participants.

Growing Clinical Research Demand and Biopharmaceutical R&D Drive Market Growth

The increasing number of clinical trials, rising prevalence of chronic diseases, growing oncology research, and expanding demand for personalized medicine are driving the Clinical Trials Market. Higher biopharmaceutical R&D expenditure and the need for new drugs, vaccines, biologics, medical devices, and advanced therapies are increasing demand for clinical research services, patient recruitment, laboratory services, bioanalytical testing, clinical trial data management, site identification, and protocol designing. Growing adoption of decentralized clinical trials, virtual trials, real-world evidence, AI, machine learning, telemedicine, and remote patient monitoring is further improving trial efficiency, patient access, data collection, and clinical research outcomes.

High Clinical Trial Costs and Stringent Regulations Restrain Market Growth

The high cost of conducting clinical trials, stringent regulatory requirements, complex approval procedures, patient recruitment difficulties, and substantial infrastructure requirements can restrain the growth of the Clinical Trials Market. Clinical studies often require significant investment in laboratory testing, clinical data management, trial monitoring, regulatory compliance, patient safety, technology integration, and specialized research personnel. Differences in regulatory standards across countries, data security concerns, ethical issues, complex trial designs, and delays in translating successful studies into market approvals can further increase clinical trial timelines, operational complexity, and overall development costs.

Decentralized Trials, AI, and Real-World Evidence Create Opportunities

Advancements in AI-driven clinical trials, machine learning, predictive analytics, decentralized clinical trials, virtual trial platforms, remote monitoring, wearable technologies, adaptive trial designs, and real-world evidence are creating significant opportunities in the Clinical Trials Market. These technologies can improve protocol design, patient identification, patient recruitment, clinical data collection, trial monitoring, decision-making, and research efficiency. Growing adoption of synthetic control arms, biomarker-driven trials, digital health technologies, patient-centric trial models, and healthcare-system partnerships is further encouraging pharmaceutical companies, biotechnology firms, CROs, research institutions, and healthcare organizations to adopt advanced clinical trial technologies.

Patient Recruitment, Regulatory Complexity, and Data Security Create Challenges

Recruiting and retaining suitable patients, complying with diverse regulatory requirements, protecting sensitive clinical trial data, and managing increasingly complex clinical study designs remain major challenges for the Clinical Trials Market. Multi-country clinical trials may face differences in drug approval standards, ethical requirements, patient safety regulations, and operational procedures. Integration of advanced technologies such as AI, blockchain, remote monitoring systems, virtual clinical trial platforms, and clinical data management technologies also requires substantial investment and infrastructure changes. These factors can increase clinical trial costs, extend development timelines, complicate trial execution, and create additional operational challenges for sponsors and clinical research organizations.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/189646/

Global Clinical Trials Market Segmentation

The Global Clinical Trials Market is segmented by Phase, Study Design, Service Type, Indication, and Region. Rising clinical research activity, increasing biopharmaceutical R&D expenditure, growing demand for personalized medicine, expansion of oncology and chronic disease research, and increasing adoption of decentralized trials, AI, machine learning, and real-world evidence are supporting market development across these segments.

North America Leads the Clinical Trials Market While Asia Pacific Expands Clinical Research Activity

North America leads the Global Clinical Trials Market, supported by high clinical research activity, strong pharmaceutical and biotechnology industries, advanced healthcare infrastructure, significant biopharmaceutical R&D expenditure, and the presence of major clinical research organizations. The United States remains a major market due to extensive Phase I–IV trial activity, rising oncology research, chronic disease burden, and growing adoption of decentralized clinical trials, AI, machine learning, real-world evidence, and remote patient monitoring. Canada also supports market growth through government investment in clinical trial infrastructure.

Europe remains an important market, supported by established pharmaceutical industries, strong academic research networks, advanced healthcare systems, and continued clinical trial activity across oncology, cardiovascular diseases, CNS conditions, diabetes, obesity, and autoimmune disorders. The UK, France, Germany, Italy, Spain, Sweden, Austria, and other European countries contribute to regional growth.

Beast and Edge of Hell Open for the Season as Festival of the Full Moon

Celebrates Boo in the Bottoms, October 2-4

KANSAS CITY, Mo., Sept. 25, 2026 /PRNewswire/ -- Halloween officially comes alive in Kansas City when the Historic West Bottoms celebrates Boo in the Bottoms during First Friday Weekend, October 2-4. This year's event brings a new twist as the daytime festival, filled with shopping, music, Thriller-themed dance instruction, costumed characters, and family fun, transforms into a nighttime destination for thrill-seekers when legendary haunted attractions Beast and Edge of Hell open their 2026 seasons on Friday, October 2.

Daytime treats: the West Bottoms is filled with treasure hunters searching for vintage finds, seasonal décor, antiques, gifts, and one-of-a-kind discoveries across 13 blocks of historic buildings. Costumed visitors can trick-or-treat at participating stores, gather around boo-tiful fire pits for s'mores, enjoy festive drinks from the Full Moon Street Bar, and meet friendly haunt characters roaming the district for photos and laughs.

Music in the streets adds to the fall atmosphere, while on Saturday from 11 a.m -2 p.m, visitors can also learn the iconic moves to Michael Jackson's "Thriller" during free, special dance instruction sessions led by D3 Stepper, creating a playful celebration for anyone who wants to join in the famous zombie moves. Bring the kids to trick-or-treat in participating stores.

"Boo in the Bottoms is when we kick off Halloween Kansas City-style," said Amber Arnett-Bequeaith, Queen of Haunts and spokesperson for the district. "Come down during the day and get into some good trouble. Hunt for vintage treasures, learn the 'Thriller' dance or watch the dancers, and get your picture with our haunt characters before they go to work. Then Friday night, things take a darker turn. Beast and Edge of Hell open their doors for the season, and after that, you're on your own. With only 13 October nights to get your haunt fix, maybe 13 isn't unlucky after all. It's time to stir the cauldron, make some memories, and find out why generations of Kansas Citians keep coming back to get scared."

The same streets where shoppers searched for treasures become the gateway to two of Kansas City's legendary haunted attractions, turning the district from vintage to vampires, from treats to terrors, and from shopping destination to Halloween headquarters.

BOO IN THE BOTTOMS WEEKEND PLANNER

- West Bottoms Shopping — West Bottoms Shopping — More than 30 stores, restaurants, and entertainment venues will be open throughout the Festival of the Full Moon weekend. Most shops are open from 9 a.m. to 6 p.m. Friday and Saturday and 11 a.m. to 4 p.m. Sunday. Hours vary by business.

Featured Businesses — Throughout the 13-block district, visitors will find a mix of shopping, dining, and entertainment.

- All Keyed Up Piano Shop – www.allkeyeduppiano.com

- Amigoni Urban Winery – www.amigoni.com

- Bella Patina www.bellapatinakc.com

- Brass Pig

- Chef J's Barbecue www.chefjbbq.com

- Good JuJuwww.goodjujukc.com

- Java Garage www.thejavagarage.com

- Robins Nest www.facebook.com/therobinsnestwestbottoms

- Rustic Vintage Rose www.facebook.com/RusticVintageRose

- Serendipity

- Treasures on 13th 2 stores, 2nd floor and street level in the Central Bag Building www.facebook.com/treasureson13thstKC

- Ugly Glasswww.facebook.com/UglyGlassCo

- Charmed House www.charmedhouseinteriors.com

- West Bottoms Whiskey Co - www.westbottomswhiskey

- Halloween Fun & Meet-and-Greet Haunt Characters — Family-friendly scare cast members will roam outside Friday and Saturday from 10 a.m. to 3 p.m. and Sunday from noon to 3 p.m. Guests are encouraged to wear costumes, take photos, and trick-or-treat at participating stores.

- Street Music & Thriller Dance Instruction — Enjoy live entertainment in the streets and learn the famous "Thriller" dance at no cost for a fun led by dance instructor D3 Stepper, this is an interactive zombie groove experience for all ages. Saturday 11- 2 p.m.

- Food & Drink — Indulge at Chef J BBQ, Java Garage, Bella Patina's Painted Rooster Café, West Bottoms Whiskey, and the Full Moon Street Bar.

- Fire Pits & Full Moon Street Bar — Gather around glowing fire pits with your boo, roast s'mores, sip seasonal beverages, and enjoy the fall atmosphere. Available Friday, Saturday and Sunday 9-5pm

- Haunted Attractions Opening Night — Beast and Edge of Hell open for the 2026 season beginning Friday, October 2, with a total of just 13 nights scheduled throughout October. Visit attraction websites for dates, times, and tickets. www.kcbeast.comwww.edgeofhell.com

- KC Collectors Spooky Plant Sale — Saturday, October 3, from 9 a.m. to 5 p.m. - featuring plant vendors, Halloween-themed items, candy, costumes, and collectibles.

This year, Beast and Edge of Hell have just 13 nights on the October schedule, followed by the remaining 2026 West Bottoms First Friday Weekend events: Blessings in the Bottoms, Nov. 6-8, and Bows in the Bottoms, each weekend in December prior to Christmas, beginning Dec. 4-6.

About the Historic West Bottoms Entertainment District

The Historic West Bottoms Entertainment District, located just off the 12th Street Bridge, encompasses a 13-block district of historic warehouses filled with hundreds of vendors, shops, restaurants, and entertainment venues. The district's multi-story buildings date back well over a century. These repurposed, vast spaces form the largest indoor vintage entertainment district operating year-round. The West Bottoms is the destination for interior decorators, designers, collectors, and consumers seeking stylish décor and gift options with a one-of-a-kind history and patina. westbottoms.com

SOURCE Historic West Bottoms District

Share this article

PUNE, India, Sept. 25, 2026 /PRNewswire/ -- The Global Dietary Supplements Market was valued at USD 186.36 Billion in 2025 and is projected to grow at a 6.37% CAGR from 2026 to 2034, reaching USD 324.88 Billion by 2034, according to Maximize Market Research.

Global Dietary Supplements Market

The Global Dietary Supplements Market Report 2026 provides a detailed analysis of market trends, consumer demand, health and wellness trends, preventive healthcare, personalized nutrition, regulatory developments, technological innovation, competitive developments, product categories, distribution channels, and market forecasts through 2034. The market covers Vitamins, Botanicals, Minerals, Proteins & Amino Acids, Fibers & Specialty Carbohydrates, Omega Fatty Acids, Probiotics, Prebiotics & Postbiotics, and Others, with forms including Tablets, Capsules, Soft Gels, Powders, Gummies, Liquid, and Others. Applications span Energy & Weight Management, General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-cancer, Lungs Detox/Cleanse, and Others.

The growing focus on health consciousness, preventive healthcare, immunity, fitness, healthy ageing, mental well-being, and personalized nutrition is supporting the expansion of the Global Dietary Supplements Market. Increasing consumer adoption of vitamin supplements, mineral supplements, herbal supplements, probiotics, sports nutrition, immunity boosters, botanical extracts, and functional supplements is strengthening demand across major markets. Rising preference for plant-based supplements, vegan supplements, organic formulations, clean-label dietary supplements, Ayurvedic supplements, and natural ingredients is further reshaping product development and consumer purchasing patterns.

Advancements in AI-driven personalized nutrition, DNA-based supplement recommendations, microbiome testing, smart wearables, liposomal formulations, transparent liquid capsules, and sustained-release tablets are transforming the dietary supplements landscape. Increasing innovation in personalized wellness, functional nutrition, clean-label nutraceuticals, sports nutrition, gut health, stress management, sleep support, immunity, and weight management is creating new opportunities for market participants. Product launches, digital health integration, e-commerce expansion, strategic partnerships, and growing investment in natural and plant-based formulations are expected to strengthen the Global Dietary Supplements Market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/26277/

Global Dietary Supplements Market gains momentum as rising health consciousness, preventive healthcare, personalized nutrition, growing demand for vitamins, minerals, probiotics, herbal and plant-based supplements, expansion of clean-label and vegan formulations, and increasing adoption of AI-driven nutrition technologies accelerate market growth: Maximize Market Research unveils key insights.

Global Dietary Supplements Market Size & Forecast

Global Dietary Supplements Market Trends & Insights

- North America leads the Global Dietary Supplements Market, supported by high consumer spending on health and wellness, strong preventive healthcare awareness, high adoption of vitamins, minerals, herbal supplements, probiotics, and sports nutrition products, regulatory clarity, and the presence of major dietary supplement manufacturers. The United States remains a key contributor to regional market growth.

- Rising health consciousness, preventive healthcare, fitness awareness, healthy ageing, immunity, mental well-being, and personalized nutrition are accelerating consumer adoption of nutritional supplements, vitamin supplements, mineral supplements, herbal supplements, probiotics, botanical extracts, and functional supplements worldwide.

- Growing demand for plant-based supplements, vegan supplements, organic products, clean-label formulations, Ayurvedic supplements, herbal nutraceuticals, and natural ingredients is reshaping product development. The United States, Europe, India, China, and Japan are witnessing increasing demand for botanical and naturally derived dietary supplements.

- AI-driven personalized nutrition, DNA-based supplement recommendations, microbiome testing, smart wearables, liposomal formulations, transparent liquid capsules, and sustained-release tablets are gaining importance as companies focus on improved bioavailability, personalized health solutions, and enhanced consumer experience.

- Innovation in personalized wellness, immunity-boosting supplements, sports nutrition, protein supplements, botanical blends, clean-label nutraceuticals, and plant-based formulations is intensifying competition. E-commerce, digital-first supplement brands, subscription models, influencer marketing, and AI-enabled personalized nutrition are further transforming the Global Dietary Supplements Market and creating new opportunities through 2034.

Increasing Health Consciousness and Preventive Healthcare Drive Market Growth

The rising focus on health consciousness, preventive healthcare, immunity, fitness, healthy ageing, mental well-being, and personalized nutrition is driving the Dietary Supplements Market. Consumers are increasingly adopting vitamin supplements, mineral supplements, herbal supplements, probiotics, sports nutrition products, botanical extracts, and functional supplements as part of daily wellness routines. Growing demand for multifunctional dietary supplements, weight management products, energy supplements, stress-relief products, sleep-support supplements, and gut-health formulations is further strengthening long-term market demand.

Regulatory Complexity and Compliance Costs Restrain Market Growth

Regulatory challenges remain a major restraint for the Dietary Supplements Market as manufacturers must comply with different frameworks across the United States, Europe, India, and other markets. Strict requirements related to safety testing, ingredient verification, labeling, documentation, health claims, quality control, and third-party certification can increase development costs and delay product launches. Regulatory uncertainty, contamination risks, adulterated products, misleading claims, and product recalls can also reduce consumer confidence and limit market expansion.

Plant-Based, Natural, and Personalized Nutrition Create Opportunities

Growing demand for plant-based supplements, natural ingredients, vegan supplements, clean-label formulations, Ayurvedic supplements, botanical extracts, and herbal nutraceuticals is creating significant opportunities in the Dietary Supplements Market. Consumers are shifting away from synthetic formulations toward products positioned around purity, sustainability, natural sourcing, and preventive wellness. Rising adoption of AI-driven personalized nutrition, DNA-based supplement recommendations, microbiome testing, smart wearables, liposomal formulations, and sustained-release technologies is further expanding opportunities for product innovation and customized health solutions.

Quality, Safety, Consumer Trust, and Product Differentiation Create Challenges

Maintaining product quality, ensuring ingredient safety, validating health claims, and building consumer trust remain key challenges for Dietary Supplements Market participants. Companies must manage increasingly complex expectations around clean-label products, transparency, certifications, efficacy, natural ingredients, and regulatory compliance while competing across vitamins, minerals, probiotics, sports nutrition, herbal supplements, and functional nutrition categories. Rapid product innovation, digital-first brands, e-commerce expansion, and increasing competition from regional and global manufacturers are also raising the need for stronger differentiation, credible claims, and consistent product quality.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/26277/

Global Dietary Supplements Market Segmentation

The Global Dietary Supplements Market is segmented by Product, Form, Type, Application, End User, Distribution Channel, and Region. The market covers a broad range of vitamins, botanicals, minerals, proteins and amino acids, probiotics, specialty nutritional products, and multiple dosage formats serving general health, immunity, weight management, bone and joint health, gastrointestinal health, cardiac health, and other wellness applications.

North America Leads the Dietary Supplements Market While Asia Pacific Strengthens Nutraceutical Demand

North America leads the Global Dietary Supplements Market, supported by high health awareness, strong preventive healthcare adoption, and widespread use of nutritional supplements. The United States shows strong demand for vitamin supplements, mineral supplements, herbal supplements, probiotics, sports nutrition products, immunity supplements, and plant-based supplements.

Europe remains an important market for dietary supplements, vegan supplements, botanical products, clean-label nutraceuticals, and immunity supplements. Growing preference for natural ingredients, responsible sourcing, sustainability, and product transparency continues to influence dietary supplement demand across European countries.

Asia Pacific is gaining importance in the Dietary Supplements Market, particularly across China, Japan, India, South Korea, and Australia. Demand for Ayurvedic supplements, herbal supplements, plant-based dietary supplements, vitamins, botanical products, and preventive health products is expanding across the region.

KALAMAZOO, Mich., Sept. 25, 2026 /PRNewswire/ -- The Drive for Life Foundation celebrated 44 years of giving in a big way by raising $1.5 million for charity during its Drive for Life Foundation Gala on Thursday, September 24th at the Radisson Plaza Hotel at Kalamazoo Center.

The event brought together business leaders, sponsors, community members and special guests for an evening dedicated to supporting the American Cancer Society and local charitable organizations that provide critical resources and services throughout the community.

"The success of this year's Gala belongs to the entire community," said Aaron Zeigler, president of Zeigler Auto Group and a presenting sponsor of the Drive for Life Foundation Gala.

"We are grateful to every sponsor, donor, volunteer and guest who helped make it possible. For 44 years, this event has demonstrated the generosity of West Michigan, and tonight was another powerful example of that spirit."

The evening featured MSU football coach Pat Fitzgerald as the special guest speaker and Portage native and Zeigler-sponsored NASCAR driver Carson Hocevar as a celebrity guest.

Fitzgerald, a former standout linebacker at Northwestern and two-time consensus All-American, was inducted into the College Football Hall of Fame in 2008. Before becoming head football coach for the MSU Spartans, Fitzgerald spent 17 seasons as Northwestern's head coach, compiling 110 victories, the most in school history. He led the Wildcats to 10 bowl appearances, two Big Ten West Division titles and five AP Top 25 finishes.

Hocevar, who was born and raised in Portage, began racing at age seven and went on to compete full-time in the NASCAR Cup Series beginning in 2024. He earned his first Cup Series victory at Talladega Superspeedway in April 2026.

Guests at the Gala enjoyed a social cocktail hour, silent auction, live auction and other activities throughout the evening, all supporting the Foundation's charitable mission.

The 44th Annual Drive for Life Foundation Gala was presented by Zeigler Auto Group, Greenleaf Trust, Brown & Brown Dealer Services, Cox Automotive and Huntington National Bank, with additional support from sponsors and community partners.

About the Drive for Life Foundation Gala

For more than four decades, the Drive for Life Gala has brought together business leaders, sponsors and community members for an extraordinary night of giving.

The event debuted in 1982 with a starting ticket price of just $1, raising less than $20,000 for the American Cancer Society. Today, the Drive for Life Gala benefits the American Cancer Society and other local charities, raising hundreds of thousands of dollars annually.

For more information visit driveforlifefoundation.org

MEDIA CONTACT

Francis Mariela | 239.273.6976

[email protected]

SOURCE Zeigler Automotive Group

Share this article

MISSISSAUGA, ON, Sept. 25, 2026 /PRNewswire/ -- Kye Pharmaceuticals is pleased to announce it has ranked No. 105 on the 2026 Report on Business magazine's ranking of Canada's Top Growing Companies.

Canada's Top Growing Companies ranks Canadian companies on 3-year revenue growth. Kye Pharmaceuticals earned its spot with 3-year growth of 264%.

"This is our 2nd year in a row being recognized on Canada's Top Growing Companies list and we are grateful to the team at the Globe & Mail for this recognition, drawing attention to our progress in bringing medicines to Canada that fill areas of high unmet medical need" says John McKendry, President & CEO at Kye Pharmaceuticals. "Our growth is a measure of success for the team and a reflection of the value our medicines are delivering for an increasing number of patients across Canada."

Canada's Top Growing Companies is an editorial ranking that launched in 2019 to celebrate the achievements of innovative businesses in Canada. To qualify for this program; companies voluntarily completed an in-depth application process and fulfilled targeted revenue requirements. In total, 376 companies earned a spot on this year's ranking.

The full list of 2026 winners along with editorial coverage is published in the October issue of Report on Business magazine. The list is also published online here Ranking Canada's Top Growing Companies of 2026 - The Globe and Mail.

"Our annual ranking of Canada's Top Growing Companies celebrates the innovation, ambition and resilience of businesses across the country, and we're always excited to share as many of these standout stories as we can— including insight from the entrepreneurs themselves on how other companies can succeed, too." says Dawn Calleja, editor of Report on Business magazine.

"The Globe and Mail congratulates the winners of Canada's Top Growing Companies 2026 on this exceptional achievement" says Andrew Saunders, president and CEO of The Globe and Mail. "Each of these organizations has shown an extraordinary ability to adapt, innovate and grow amid ongoing change. Their achievements reflect the ingenuity and determination of Canadian entrepreneurs and business leaders who are helping shape the future of our economy."

About The Globe and Mail

The Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.1 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.7 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.

About Kye Pharmaceuticals

Kye is a leading growth-stage Canadian specialty pharmaceutical company committed to bringing value to Canadians by identifying, licensing, and commercializing novel prescription medicines that may not otherwise be available to patients across Canada. With a growing pipeline of innovative medicines, Kye's portfolio spans a range of therapeutic areas including cardiology, psychiatry, pediatrics, rare diseases, neuromuscular, hematology, and neurology. Kye Pharmaceuticals is a private company, founded in Canada and focused exclusively on the healthcare needs of patients in Canada. Kye aims to provide medicines that deliver better outcomes to our partners, Canadian healthcare professionals, and most importantly, patients across Canada. Kye, headquartered in Mississauga, Ontario was recognized on the Globe & Mail 2025 Canada's Top Growing Companies list.

For more information about the company, its management, portfolio, pipeline and commitment, please visit www.kyepharma.com

SOURCE Kye Pharmaceuticals Inc.

Share this article

CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided a business update with corporate highlights to date and financial results for the first half of 2026.

NeuroSense is advancing PrimeC, its investigational combination therapy for amyotrophic lateral sclerosis (ALS), through regulatory pathways in the United States and Canada while pursuing a focused, capital-efficient late-stage development strategy.

"Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "We are working diligently to move our development plans forward in a capital-efficient manner, while pursuing the regulatory, clinical, financing and strategic opportunities available to us. Looking ahead, our priorities include advancing our regulatory pathway in Canada, preparing for the next clinical stage of PrimeC in ALS, and pursuing the funding, partnerships and strategic alternatives that can support the continued development of the program. We remain fully committed to doing everything we can to realize PrimeC's potential to address the significant unmet need in ALS."

Upcoming Corporate Highlights for the Remainder of 2026 include:

- Targeting December 2026 NDS filing in Canada – Following completion of the Pre-New Drug Submission process and finalization of meeting minutes with Health Canada, NeuroSense is preparing an NDS for PrimeC in ALS and is targeting December 2026 for submission. Health Canada indicated no concerns with the proposed filing timeline and provided alignment regarding the planned content and structure of the submission.

- Advancing an optimized, capital-efficient U.S. development strategy – NeuroSense is working toward an optimized path for PrimeC that includes AI-enabled characterization of PrimeC's proprietary formulation, a planned active-comparator study against edaravone, and evaluation of a smaller and shorter pivotal PARAGON design. The Company plans to discuss with the FDA whether the existing data may support full approval or, alternatively, an Accelerated Approval pathway. Any revised pivotal design or regulatory pathway remains subject to FDA alignment.

- Continued financing and strategic initiatives – The Company continues to pursue financing opportunities, including potential non-dilutive funding sources, and evaluate a range of strategic alternatives, including potential business and corporate transactions, intended to provide the resources and strategic framework required to advance PrimeC, while prioritizing capital-efficient development and preserving long-term shareholder value.

2026 Corporate Highlights to Date

- PARADIGM results published in JAMA Neurology and long-term survival benefit strengthened – In March 2026, results from the Phase 2b PARADIGM study were published in JAMA Neurology, providing peer-reviewed validation of PrimeC's clinical and biological activity. Long-term follow-up reported in February 2026 showed a statistically significant 65% reduction in the risk of death and an estimated median survival of 36.3 months for participants treated continuously with PrimeC, compared with 21.4 months for participants initially assigned to placebo before crossing over to PrimeC.

- Primary  endpoint achieved – In June 2026, NeuroSense announced that PARADIGM achieved its primary endpoint, demonstrating a statistically significant treatment-associated reduction in extracellular vesicle-associated TDP-43 compared with placebo. TDP-43 pathology is present in more than 97% of ALS cases, and the finding adds to the consistent body of evidence observed across clinical outcomes, survival and multiple disease-relevant biomarkers.

- Canadian regulatory pathway advanced toward NDS filing – NeuroSense held a constructive Pre-NDS meeting with Health Canada and subsequently completed the Pre-NDS process. Final meeting minutes reflected alignment on the planned content and structure of the ALS submission, and the Company is now targeting an NDS filing in early December 2026, supported by the expanded PARADIGM clinical, survival and biomarker package.

- Alzheimer's program and global intellectual property portfolio advanced – The Phase 2 RoAD proof-of-concept study reported positive biomarker findings across multiple neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement. NeuroSense also strengthened its Alzheimer's program through a U.S. patent covering use of PrimeC through 2043 and the addition of Prof. Steven E. Arnold to its Scientific Advisory Board. During 2026, the Company further expanded PrimeC composition patent protection through 2042 with grants in Australia, Brazil, Japan and South Korea.

H1 2026 Financial Results:

- Research and development expenses for the six months ended June 30, 2026 and 2025 were $2,102 thousand and $2,503 thousand, respectively. The decrease of $401 thousand, or 16%, was mainly attributed to decrease in our subcontractors and consultants which was offset by an increase in share-based payment expense.

- General and administrative expenses for the six months ended June 30, 2026 and 2025 were $1,345 thousand and $2,189 thousand, respectively. The decrease of $844 thousand, or 38.6%, was mainly attributed to decrease in professional services.

- Operating expenses for the six months ended June 30, 2026 and 2025 were $3.4 million and $4.7 million, respectively due to the reasons described above.

A summary of NeuroSense's unaudited consolidated financial results is included in the tables below.

About ALS

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within approximately 3 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

About PARADIGM

PARADIGM is a prospective, multinational, randomized, double-blind, placebo-controlled Phase 2b (NCT05357950) clinical trial of PrimeC in ALS. The trial included 68 participants living with ALS in Canada, Italy, and Israel.

During the first 6 months of the trial, 45 participants were randomized to receive PrimeC, and 23 participants were randomized to receive placebo. This was followed by a 12-month open-label extension with all participants receiving PrimeC in a blinded manner, where neither the participants nor the clinical staff were aware of the initial treatment allocation.

Most patients enrolled in both the active and placebo arms of the trial were concurrently treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease progression well beyond the level afforded by the FDA approved ALS drug.

About PrimeC

PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. PrimeC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has recently completed analysis of long-term follow-up data from its Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology showing slowing of functional decline relative to placebo. The Company also reported changes across multiple biomarkers associated with ALS, including microRNAs, consistent with PrimeC's multi-target mechanism of action.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be conducted primarily in the United States. As described above, the Company is working with FDA on an optimized design for the study.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words.

KANSAS CITY, Mo., Sept. 25, 2026 /PRNewswire/ -- Marking the wind down of baseball season, Sun Life U.S. and the Kansas City Royals Foundation have successfully completed the first "Every Single Smile" campaign, reaching their $50,000 goal to help TeamSmile expand access to dental care for youth in underserved communities across Kansas City. TeamSmile is a leading nonprofit organization providing large-scale dental clinics for local children in cities throughout the country, in partnership with professional sports organizations. Through this season-long initiative, every Royals single generated a donation from Sun Life and the KC Royals Foundation.

The campaign represents an evolution of the long-standing commitment to community health that Sun Life and the Royals have shared throughout their nearly decade-long partnership. Building on the previous success of the annual "Strike Out Diabetes" fundraising initiative, the partnership expanded this year to include oral health as a critical component of overall wellness for vulnerable populations.

"Every Single Smile" demonstrates how meaningful partnerships can drive real health outcomes," said Todd Gray, DDS, Chief Dental Officer, Sun Life U.S., including DentaQuest, and board member of TeamSmile. "Through our commitment to broadening healthcare access, our work with the Royals and their devoted fans helps connect a beloved pastime to improved access to dental services for youth across Kansas City. When we help kids get the dental care they need, they are far more likely to maintain their oral health into adulthood."

The funds will help TeamSmile host an additional dental clinic this December in Kansas City and strengthen the Dental Home Project, connecting underserved youth with local dentists to establish ongoing relationships and preventive care. As a benefits provider, Sun Life is strongly focused on helping broaden access to care, working with philanthropic partners to support programs that serve vulnerable communities.

"The enthusiasm from our fans and the dedication from Sun Life made this campaign a tremendous success," said Drew Fuemmeler, vice president of Corporate Partnerships, Kansas City Royals. "Together, we're creating lasting change in our community health landscape by helping connect kids to better oral health."

Sun Life U.S. has been a partner of the Kansas City Royals since 2017, renewing the partnership last year through the 2030 baseball season. Sun Life is also a sponsor and partner of the Boston Celtics and Maine Celtics, and sponsors TeamSmile events in multiple cities around the country.

Click here to learn more about Sun Life's philanthropic partnerships and programming.

About Sun Life

Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of June 30, 2026, Sun Life had total assets under management of C$1.70 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Sun Life U.S. is one of the largest providers of employee and government benefits, helping approximately 48 million Americans access the care and coverage they need. Through employers, industry partners and government programs, Sun Life U.S. offers a portfolio of benefits and services, including dental, vision, disability, absence management, life, supplemental health, medical stop-loss insurance, and healthcare navigation. Sun Life employs more than 8,300 people in the U.S., including associates in our partner dental practices and affiliated companies in asset management. Group insurance policies are issued by Sun Life Assurance Company of Canada (Wellesley Hills, Mass.), except in New York, where policies are issued by Sun Life and Health Insurance Company (U.S.) (Lansing, Mich.). For more information visit our website and newsroom.

About The Kansas City Royals

The Kansas City Royals are a Major League Baseball team operated by a hometown ownership group led by Chairman and CEO John Sherman. Ewing Kauffman founded the club in 1969 because, in his words, "I believe the people of Kansas City deserved a Major League Baseball team." No MLB team founded along with or since can match the Royals four American League pennants and two World Series Championships. Since Sherman's purchase, the Royals won the Bud Selig Award for Philanthropic Excellence in 2021 and been a finalist three other times.

Media contacts

Devon Fernald

Sun Life U.S.

[email protected]

781-800-3609

Kindle Biermann

Kansas City Royals

[email protected] 

SOURCE Sun Life U.S.

Share this article

KLX Energy Services Holdings, Inc. Updates 2026 Third Quarter Guidance

Tightens its Revenue range versus prior guidance and provides Adjusted EBITDA Margin range of 13% to 14%

HOUSTON, Sept. 25, 2026 /PRNewswire/ -- KLX Energy Services Holdings, Inc. (Nasdaq: KLXE) ("KLX", the "Company", "we", "us" or "our") today announced it has updated its 2026 third quarter Revenue range to tighten its previously announced guidance; and provides Adjusted EBITDA Margin range for the third quarter that ends September 30, 2026.

Third Quarter 2026 Guidance Update

- Estimated 3Q26 Revenue range is now $180 million to $185 million, representing a 9% sequential Revenue improvement over the second quarter of 2026

- Estimated 3Q26 Adjusted EBITDA Margin range is 13% to 14%, representing an approximately 200 basis point sequential Adjusted EBITDA Margin improvement over second quarter of 2026

Chris Baker, KLX President and Chief Executive Officer, stated, "Based on our quarter to date internal financials, we are very pleased with our performance thus far in the third quarter. Looking at our current internal forecast, we are narrowing our third quarter revenue guidance to a range of $180 million to $185 million. At the revised midpoint, we expect revenue will increase approximately 9% sequentially over the second quarter of 2026.

"We expect Adjusted EBITDA to improve by approximately 30% at the midpoint of the guidance range and Adjusted EBITDA Margin to improve approximately 200 basis points sequentially.

"We are also benefiting from a full quarter of contribution from the Wolf Pack acquisition, and we remain on track to achieve the $2.5 million annual synergy target announced in August. These updated ranges for the third quarter reinforce our confidence in the earnings trajectory of the business and support the strategic actions we have taken to position KLX for the next phase of growth.

"Lastly, the offering period for the Company's $125 million equity rights offering has ended and we are proud to have achieved the Company's objectives. This is a transformational step in the Company's strategy to delever and positions KLX to execute on organic and inorganic growth. We sincerely thank our stockholders and creditors for their confidence in the Company and we appreciate the broad participation across the investor base including existing and new stockholders, creditors, the board, management and our employees."

About KLX Energy Services Holdings, Inc.

KLX is a growth-oriented provider of diversified oilfield services to leading onshore oil and natural gas exploration and production companies operating in both conventional and unconventional plays in all of the active major basins throughout the United States. The Company delivers mission critical oilfield services focused on drilling, completion, production, and intervention activities for technically demanding wells from over 60 service and support facilities located throughout the United States. KLX's complementary suite of proprietary products and specialized services is supported by technically skilled personnel and a broad portfolio of innovative in-house manufacturing, repair and maintenance capabilities. More information is available at www.klx.com.

Forward-Looking Statements and Cautionary Statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements to encourage companies to provide prospective information to investors. This news release includes forward-looking statements that reflect our current expectations and projections about our future results, performance and prospects. Forward-looking statements include all statements that are not historical in nature and are not current facts. When used in this news release (and any oral statements made regarding the subjects of this release, including on the conference call announced herein), the words "believe," "expect," "plan," "intend," "anticipate," "estimate," "predict," "potential," "continue," "may," "might," "should," "could," "will" or the negative of these terms or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on our current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events with respect to, among other things: our operating cash flows; the availability of capital and our liquidity; our future revenue, income and operating performance; our ability to sustain and improve our utilization, revenue and margins; our ability to maintain acceptable pricing for our services; future capital expenditures; our ability to finance equipment, working capital and capital expenditures; our ability to execute our long-term growth strategy and to integrate our acquisitions; our ability to successfully develop our research and technology capabilities and implement technological developments and enhancements; and the timing and success of strategic initiatives and special projects.

Forward-looking statements are not assurances of future performance and actual results could differ materially from our historical experience and our present expectations or projections. These forward-looking statements are based on management's current expectations and beliefs, forecasts for our existing operations, experience, expectations and perception of historical trends, current conditions, anticipated future developments and their effect on us and other factors believed to be appropriate. Although management believes the expectations and assumptions reflected in these forward-looking statements are reasonable as and when made, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all). Our forward-looking statements involve significant risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. Known material factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, risks associated with the following: prevailing market conditions, the successfully meeting the closing conditions of the subscription rights offering and related Backstop Exchange, a decline in demand for our services, including due to overcapacity and other competitive factors affecting our industry; the cyclical nature and volatility of the oil and gas industry, which impacts the level of exploration, production and development activity and spending patterns by oil and natural gas exploration and production companies; a decline in, or substantial volatility of, crude oil and gas commodity prices, which generally leads to decreased spending by our customers and negatively impacts drilling, completion and production activity; inflation; changes in interest rates; the ongoing war in Ukraine and its continuing effects on global trade; the ongoing conflict and tensions in the Middle East, including the conflict with Iran; supply chain issues; general economic, financial and political conditions, including market volatility and the impact of the imposition of increased, new and retaliatory tariffs; and other risks and uncertainties listed in our filings with the U.S. Securities and Exchange Commission, including our Current Reports on Form 8-K that we file from time to time, Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except as required by law.

Information Regarding Guidance Updates

The Company intends to provide a detailed operational and financial update during its third quarter 2026 earnings call in November 2026. Closing procedures for the fiscal quarter ended September 30, 2026, are not yet complete. The updated guidance ranges contained in this news release reflect management's estimates based solely upon information available to it as of the date of this news release and is not a comprehensive statement of the Company's financial results for the three months ended September 30, 2026. The guidance presented herein should not be considered a substitute for full unaudited financial statements for the three months ended September 30, 2026, once they become available and should not be regarded as a representation by the Company or its management as to its actual financial results for the three months ended September 30, 2026. The guidance ranges described above constitute forward-looking statements. The guidance ranges presented herein are subject to change, and the Company's actual financial results may differ from such guidance and such differences could be material. Accordingly, you should not place undue reliance upon these guidance.

Non-GAAP Financial Measures

This release includes Adjusted EBITDA and Adjusted EBITDA margin. Each of the metrics are "non-GAAP financial measures" as defined in Regulation G of the Securities Exchange Act of 1934. We have not provided reconciliations of our future expectations as to Adjusted EBITDA or Adjusted EBITDA margin as such reconciliation is not available without unreasonable efforts.

Adjusted EBITDA is a supplemental non-GAAP financial measure that is used by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. Adjusted EBITDA is not a measure of net earnings or cash flows as determined by GAAP.

TULSA, Okla., Sept. 25, 2026 /PRNewswire/ -- ONE Gas, Inc. (NYSE: OGS) today announced it will participate virtually in the Wolfe Research Utilities, Midstream & Clean Energy Conference on Sept. 29, 2026.

Sid McAnnally, chief executive officer, Curtis Dinan, president and chief operating officer, and Christopher Sighinolfi, senior vice president and chief financial officer, will conduct a series of meetings with members of the investment community.

The materials utilized at the conference are accessible on the ONE Gas website, www.onegas.com/investors/events-and-presentations.

ONE Gas, Inc. (NYSE: OGS) is a 100-percent regulated natural gas utility, and trades on the New York Stock Exchange and the NYSE Texas under the symbol "OGS." ONE Gas is included in the S&P MidCap 400 Index and is one of the largest natural gas utilities in the United States.

Headquartered in Tulsa, Oklahoma, ONE Gas provides a reliable and affordable energy choice to more than 2.3 million customers in Kansas, Oklahoma and Texas. Its divisions include Kansas Gas Service, the largest natural gas distributor in Kansas; Oklahoma Natural Gas, the largest in Oklahoma; and Texas Gas Service, the third largest in Texas, in terms of customers.

For more information and the latest news about ONE Gas, visit onegas.com and follow its social channels: @ONEGas, Facebook, LinkedIn and YouTube.

Analyst Contact: Eric Biggers

                              918-947-7238 

Media Contact:    Leah Harper

                              918-947-7123 

SOURCE ONE Gas, Inc.

Share this article

Allstream Energy Partners, SEO Experts in Oil and Gas, Awarded Gas Processing OEM Agreement

Allstream Energy Partners, SEO experts in oil and gas, won a gas processing OEM agreement covering technical content, AEO, and GEO for midstream visibility.

HOUSTON, Sept. 25, 2026 /PRNewswire/ -- Allstream Energy Partners has been awarded a Search Engine Optimization ( SEO ) agreement with a major oil and gas original equipment manufacturer (OEM) specializing in gas processing for the midstream sector.

Under the agreement, Allstream Energy Partners will develop technical content and support the OEM's search visibility through Answer Engine Optimization (AEO for Oil and Gas ) and Generative Engine Optimization ( GEO for Oil and Gas ). The work is designed to make the company's gas processing expertise easier for prospective customers to find and understand across traditional search and AI-powered discovery platforms.

"Gas processing buyers ask highly specific technical questions when evaluating equipment and solutions," said Efrain Garcia, Founder and CEO of Allstream Energy Partners. "Our role is to turn the OEM's expertise into clear, useful content that helps buyers find answers and gives AI search platforms information they can understand, summarize, and cite throughout the buyer journey."

The engagement reflects Allstream Energy Partners' focus on connecting technical knowledge with digital marketing for the energy supply chain. Its approach combines industry-focused content development with SEO, AEO, and GEO strategies to help energy companies communicate their capabilities to the people researching and evaluating suppliers.

The OEM's name and the financial terms of the agreement were not disclosed.

About Allstream Energy Partners

Allstream Energy Partners is an energy-focused marketing agency serving companies across the oil and gas, industrial, and energy supply chain. The firm helps clients strengthen digital visibility and industry authority through technical content, SEO for Oil and Gas, Answer Engine Optimization, Generative Engine Optimization, AI-optimized websites, media, and industry engagement.

Learn more at www.AllstreamEP.com

Media Contact:

Efrain Garcia

[email protected]

8324963004

Photo(s):

https://www.prlog.org/13173030

Press release distributed by PRLog

SOURCE Allstream Energy Partners

Share this article